EVFM stock forecast
Our latest prediction for Evofem Biosciences Inc's stock price was made on the March 9, 2021 when the stock price was at 2.27$.
In the short term (2weeks), EVFM's stock price should outperform the market by 5.06%. During that period the price should oscillate between -11.29% and +20.57%.
In the medium term (3months), EVFM's stock price should underperform the market by -3.41%. During that period the price should oscillate between -46.38% and +52.68%.Get email alerts
Create a solid portfolio with EVFM
About Evofem Biosciences Inc
Evofem Biosciences, Inc., is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). The Company's first commercial product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is the first and only hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy. The Company is evaluating EVO100 in a Phase 3 clinical trial, 'EVOGUARD,' for the prevention of urogenital Chlamydia trachomatis and Neisseria gonorrhoeae infection in women.
At the moment the company generates 2M USD in revenues.
On its last earning announcement, the company reported a loss of -2.27$ per share.
The book value per share is 0.20$
Three months stock forecastMarch 9, 2021
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|